{
    "clinical_study": {
        "@rank": "90696", 
        "acronym": "RDNP-2012-03", 
        "arm_group": {
            "arm_group_label": "Renal Denervation", 
            "arm_group_type": "Experimental", 
            "description": "Renal Denervation treatment"
        }, 
        "brief_summary": {
            "textblock": "This is an observational proof of concept study investigating the safety and effectiveness\n      of renal denervation to lower blood pressure in people whose blood pressure is not adequtly\n      controlled due to:\n\n        -  intolerance to antihypertensive medication\n\n        -  inability to take antihypertensive medication due to planned pregnancy\n\n        -  renal artery stenosis\n\n        -  chronic kidney disease\n\n        -  non-compliance to antihypertensive medication\n\n      A total of 125 participants, 25 from each of the groups mentioned above will be recruited to\n      the study.\n\n      The duration of this study is 36 months."
        }, 
        "brief_title": "Renal Denervation for Complicated Hypertension", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  BP \u2265140/90mmHg (or \u2265130/80mmHg for patients with diabetes)\n\n          -  Intolerance to \u22652 antihypertensive drug classes\n\n          -  Inability to take ACEI, ARBs or DRIs due to planned pregnancy\n\n          -  Renal artery stenosis\n\n          -  Chronic Kidney Disease\n\n        Exclusion Criteria:\n\n          -  renal artery anatomy ineligible for treatment\n\n          -  individual has had myocardial infarction, unstable angina or cerebrovascular accident\n             within 6 months of screening visit\n\n          -  female participants of childbearing potential must have negative pregnancy test prior\n             to treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "125", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01865253", 
            "org_study_id": "087/12", 
            "secondary_id": "1034397"
        }, 
        "intervention": {
            "arm_group_label": "Renal Denervation", 
            "description": "Renal Denervation", 
            "intervention_name": "Renal Denervation Catheter", 
            "intervention_type": "Device", 
            "other_name": "Symplicity Renal Denervation Catheter"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "renal denervation", 
            "blood pressure", 
            "cardiovascular risk", 
            "target organ damage", 
            "sympathetic activity", 
            "chronic kidney disease", 
            "non-compliance"
        ], 
        "lastchanged_date": "December 16, 2013", 
        "location": {
            "contact": {
                "email": "markus.schlaich@bakeridi.edu.au", 
                "last_name": "Markus P Schlaich, MD", 
                "phone": "+61 3 8532 1502"
            }, 
            "facility": {
                "address": {
                    "city": "Melbourne", 
                    "country": "Australia", 
                    "state": "Victoria", 
                    "zip": "3004"
                }, 
                "name": "Baker IDI Heart & Diabetes Institute"
            }, 
            "investigator": {
                "last_name": "Markus P Schlaich, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "1", 
        "official_title": "Renal Denervation for Complicated Hypertension (RDNP-2012-03)", 
        "overall_contact": {
            "email": "markus.schlaich@bakeridi.edu.au", 
            "last_name": "Markus P Schlaich, MD", 
            "phone": "+61 3 8532 1502"
        }, 
        "overall_contact_backup": {
            "email": "petra.marusic@bakeridi.edu.au", 
            "last_name": "Petra Marusic, B.App.Sci.", 
            "phone": "+61 3 8532 1734"
        }, 
        "overall_official": {
            "affiliation": "Baker IDI Heart & Diabetes Institute", 
            "last_name": "Markus P Schlaich, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in systolic and diastolic average office blood pressure from baseline to 6 months post procedure", 
            "measure": "Change in average office blood pressure", 
            "safety_issue": "No", 
            "time_frame": "baseline to 6 months post procedure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01865253"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Percentage of patients who achieved BP target at 6 months post procedure", 
                "measure": "Blood pressure control", 
                "safety_issue": "No", 
                "time_frame": "baseline to 6 months post procedure"
            }, 
            {
                "description": "Number of drugs required to reach target blood pressure", 
                "measure": "Number of drugs required to reach target blood pressure", 
                "safety_issue": "No", 
                "time_frame": "baseline to 6 months post procedure"
            }, 
            {
                "description": "Time to achieve blood pressure target", 
                "measure": "Time to achieve blood pressure target", 
                "safety_issue": "No", 
                "time_frame": "baseline to 6 months post procedure"
            }, 
            {
                "description": "Change in muscle sympathetic nerve activity, renal and whole body NA spillover", 
                "measure": "Change in sympathetic nerve activity", 
                "safety_issue": "No", 
                "time_frame": "baseline to 6 months post procedure"
            }, 
            {
                "description": "Change in left Ventricular mass index, Ejection Fraction, diastolic filling", 
                "measure": "Change in left ventricular structure and function", 
                "safety_issue": "No", 
                "time_frame": "baseline to 6 months post procedure"
            }, 
            {
                "description": "Change in Quality of life as assessed by relevant questionnaires", 
                "measure": "Change in Quality of life", 
                "safety_issue": "No", 
                "time_frame": "baseline to 6 months post procedure"
            }, 
            {
                "description": "Plasma renin activity, aldosterone, eGFR, UACR, inflammatory markers, 24hour urine creatinine clearance, sodium, fasting glucose, fasting insulin, c peptide, HOMA index, lipid profile.", 
                "measure": "Change in serum and urine Bbiochemistry", 
                "safety_issue": "No", 
                "time_frame": "baseline to 6 months post procedure"
            }, 
            {
                "description": "Change in markers of arterial stiffness including AI and PWV", 
                "measure": "Change in markers of arterial stiffness", 
                "safety_issue": "No", 
                "time_frame": "baseline to 6 months"
            }
        ], 
        "source": "Baker IDI Heart and Diabetes Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Baker IDI Heart and Diabetes Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}